Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TURQUOISE-II: Viekira Pak + RBV in HCV GT1 Cirrhosis
NCT01704755Phase 3
Key facts
- Status
- Completed
- Start
- Oct 2012
- Primary completion
- Jan 2014
- Sponsor
- AbbVie Inc.
- Modality
- Small Molecules
- Drugs
- Viekira Pak
- Conditions
- hepatitis C (HCV)
01
Overview
Phase 3, randomised, open-label trial of Viekira Pak in hepatitis C (HCV), sponsored by AbbVie Inc. Primary endpoint: Sustained Virologic Response 12 Weeks Post-treatment. Started Oct 2012; status: completed.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
Adults with chronic HCV genotype 1 infection and compensated cirrhosis (Child-Pugh score <= 6), naive or treatment-experienced (except prior DAAs).
04
Endpoints
Primary
Sustained Virologic Response 12 Weeks Post-treatment
Secondary
Percentage of Participants With On-treatment Virologic Failure
Percentage of Participants With Virologic Relapse
05
Results
Primary endpoints met
Beyond the preview
Go deeper on NCT01704755.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01704755.